MX2020003718A - Composiciones y metodos para el tratamiento de fibrosis. - Google Patents
Composiciones y metodos para el tratamiento de fibrosis.Info
- Publication number
- MX2020003718A MX2020003718A MX2020003718A MX2020003718A MX2020003718A MX 2020003718 A MX2020003718 A MX 2020003718A MX 2020003718 A MX2020003718 A MX 2020003718A MX 2020003718 A MX2020003718 A MX 2020003718A MX 2020003718 A MX2020003718 A MX 2020003718A
- Authority
- MX
- Mexico
- Prior art keywords
- fibrosis
- compositions
- treatment
- methods
- phosphatidylcholine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570847P | 2017-10-11 | 2017-10-11 | |
| PCT/US2018/055521 WO2019075277A1 (en) | 2017-10-11 | 2018-10-11 | COMPOSITIONS AND METHODS FOR TREATING FIBROSIS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003718A true MX2020003718A (es) | 2020-10-05 |
Family
ID=66101109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003718A MX2020003718A (es) | 2017-10-11 | 2018-10-11 | Composiciones y metodos para el tratamiento de fibrosis. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12544394B2 (https=) |
| EP (1) | EP3694517A4 (https=) |
| JP (1) | JP7379348B2 (https=) |
| KR (1) | KR20200068692A (https=) |
| CN (1) | CN111278441A (https=) |
| AU (1) | AU2018347527B2 (https=) |
| CA (1) | CA3084359A1 (https=) |
| IL (1) | IL273850B1 (https=) |
| MX (1) | MX2020003718A (https=) |
| SG (1) | SG11202003300WA (https=) |
| WO (1) | WO2019075277A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY210343A (en) * | 2020-06-04 | 2025-09-12 | Hovid Berhad | Composition for normalisation of fatty liver and method for producing the same |
| EP4274566A4 (en) * | 2021-01-06 | 2024-10-30 | The Trustees of Indiana University | TOCOTRIENOL COMPOSITIONS AND METHODS FOR TREATING NONALCOHOLIC STEATOHEPATITIS |
| CN112587649A (zh) * | 2021-01-19 | 2021-04-02 | 中日友好医院(中日友好临床医学研究所) | 一种三肽化合物及其铜离子螯合物在预防和治疗矽肺中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1171047A (en) * | 1915-11-10 | 1916-02-08 | John Hornagy | Car-door fastener. |
| US2282236A (en) * | 1940-06-19 | 1942-05-05 | Bay State Optical Co | Eyeglass construction |
| US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5284835A (en) * | 1992-07-31 | 1994-02-08 | Lieber Charles S | Use of dilinoleoylphosphatidylcholine (DLPC) for treatment and prevention of cirrhosis and fibrosis in the liver |
| AR002009A1 (es) * | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
| CA2181390C (en) * | 1995-07-18 | 2001-04-24 | Pankaj Modi | Phospholipid formulations |
| WO1997006784A1 (en) | 1995-08-15 | 1997-02-27 | Universite Libre De Bruxelles | Liposomes preparation method and plant |
| CA2282236A1 (en) * | 1998-11-06 | 2000-05-06 | Peter Stys | The use of excitatory amino acid transporter inhibitors to protect against cns white matter injury |
| US20040146516A1 (en) * | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
| CN1518987A (zh) * | 2000-06-02 | 2004-08-11 | 大连万友贸易有限公司 | 多聚不饱和磷脂酰胆碱的新用途 |
| US20060115523A1 (en) * | 2004-12-01 | 2006-06-01 | Konduri Kameswari S | Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal |
| US20080107723A1 (en) * | 2006-09-28 | 2008-05-08 | Perkins Walter R | Methods of Treating Pulmonary Distress |
| JP5080779B2 (ja) | 2006-10-25 | 2012-11-21 | テルモ株式会社 | リポソーム製剤の製造方法 |
| WO2011009119A2 (en) | 2009-07-17 | 2011-01-20 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating fibrotic disorders |
| CA3102008A1 (en) | 2010-06-02 | 2011-12-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| US20160015656A2 (en) * | 2010-08-05 | 2016-01-21 | Nitto Denko Corporation | Composition for regenerating normal tissue from fibrotic tissue |
| US9585930B2 (en) | 2011-03-20 | 2017-03-07 | Trustees Of Boston University | Therapeutic agent for emphysema and COPD |
| CN102631330B (zh) * | 2012-04-19 | 2013-05-29 | 海南美大制药有限公司 | 一种兰索拉唑囊泡型磷脂凝胶缓释固体制剂 |
| HK1207977A1 (en) * | 2012-04-25 | 2016-02-19 | Trustees Of Tufts College | Silk microspheres and methods for surface lubrication |
| EP2874605A1 (en) | 2012-07-18 | 2015-05-27 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
| KR20160125352A (ko) * | 2013-12-20 | 2016-10-31 | 이센셜 파마수티컬스 엘엘씨 | 세포 배양용 배지 |
| CN103816118A (zh) * | 2014-02-14 | 2014-05-28 | 西藏海思科药业集团股份有限公司 | 一种多烯磷脂酰胆碱注射用组合物及其制备方法 |
| KR20170107256A (ko) | 2016-03-15 | 2017-09-25 | 이진희 | 미백 화장료 조성물 |
| CN105997854B (zh) * | 2016-06-14 | 2018-11-27 | 成都天台山制药有限公司 | 多烯磷脂酰胆碱注射液组合物和制法 |
| CN106310220A (zh) | 2016-08-17 | 2017-01-11 | 浙江中医药大学 | 一种包封鳖甲肽的rgd‑ssl脂质体及其制备方法 |
-
2018
- 2018-10-11 JP JP2020542041A patent/JP7379348B2/ja active Active
- 2018-10-11 MX MX2020003718A patent/MX2020003718A/es unknown
- 2018-10-11 EP EP18867017.8A patent/EP3694517A4/en active Pending
- 2018-10-11 AU AU2018347527A patent/AU2018347527B2/en active Active
- 2018-10-11 CA CA3084359A patent/CA3084359A1/en active Pending
- 2018-10-11 US US16/755,245 patent/US12544394B2/en active Active
- 2018-10-11 CN CN201880070455.7A patent/CN111278441A/zh active Pending
- 2018-10-11 KR KR1020207012908A patent/KR20200068692A/ko active Pending
- 2018-10-11 SG SG11202003300WA patent/SG11202003300WA/en unknown
- 2018-10-11 WO PCT/US2018/055521 patent/WO2019075277A1/en not_active Ceased
-
2020
- 2020-04-06 IL IL273850A patent/IL273850B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200246361A1 (en) | 2020-08-06 |
| IL273850B1 (en) | 2026-01-01 |
| EP3694517A4 (en) | 2021-07-14 |
| CN111278441A (zh) | 2020-06-12 |
| IL273850A (en) | 2020-05-31 |
| AU2018347527A1 (en) | 2020-04-23 |
| JP2021502404A (ja) | 2021-01-28 |
| KR20200068692A (ko) | 2020-06-15 |
| WO2019075277A1 (en) | 2019-04-18 |
| EP3694517A1 (en) | 2020-08-19 |
| US12544394B2 (en) | 2026-02-10 |
| CA3084359A1 (en) | 2019-04-18 |
| BR112020007083A2 (pt) | 2020-09-24 |
| SG11202003300WA (en) | 2020-05-28 |
| JP7379348B2 (ja) | 2023-11-14 |
| AU2018347527B2 (en) | 2024-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002358A1 (es) | Constructos de arni para inhibir la expresión de pnpla3 y sus métodos de uso | |
| CR20210371A (es) | Constructos de arni para inhibir la expresión de pnpla3 | |
| PE20211212A1 (es) | AGENTES DE ARNi PARA INHIBIR LA EXPRESION DE 17beta-HSD TIPO 13 (HSD17B13), COMPOSICIONES DE DICHOS AGENTES, Y METODOS DE USO | |
| CY1117209T1 (el) | Συνθεσεις περιλαμβανοντας 15-ηερε και μεθοδοι χρησης των ιδιων | |
| EP4332576A3 (en) | Synergistic enhancement of the delivery of nucleic acids via blended formulations | |
| PE20180523A1 (es) | Compuestos co-agonistas del glucacon y peptido-1 similar al glugacon (glp-1) | |
| CL2020001226A1 (es) | Proceso para preparar tapinarof. | |
| MX385109B (es) | Formulaciones de anticuerpos. | |
| MX2020003718A (es) | Composiciones y metodos para el tratamiento de fibrosis. | |
| CL2019002340A1 (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1. | |
| BR112016024020A2 (pt) | composição farmacêutica | |
| MX2018005489A (es) | Agente antimicrobiano que comprende xantohumol y su uso en productos alimenticios. | |
| CL2020003456A1 (es) | Formulaciones de fgf-21 | |
| UY38733A (es) | Construcciones de arni para inhibir la expresión de scap y métodos de uso de las mismas | |
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| CO2018007112A2 (es) | Composiciones farmacéuticas que comprenden derivados de fenilaminopirimidina | |
| MX381092B (es) | Inhibidores de fucosidasa. | |
| AU2015267160A8 (en) | Methods and compositions for preventing ischemia reperfusion injury in organs | |
| CL2020000597A1 (es) | Métodos y composiciones para tratar enfermedades pulmonares crónicas. | |
| TW201613489A (en) | Hydrolyzed lactose-containing nutritional compositions and uses thereof | |
| MX2021005688A (es) | Compuestos de piridina sulfonamida para el tratamiento contra afecciones relacionadas con interleucina 1 beta. | |
| MX2019003697A (es) | Sal de metformina de elafibranor que muestra una actividad doble para el tratamiento de la obesidad asociada a la esteatohepatitis no alcoholica (nash) y a la hipertrigliceridemia. | |
| AR114739A1 (es) | AGENTES DE ARNi PARA INHIBIR LA EXPRESIÓN DE 17b-HSD TIPO 13 (HSD17B13), COMPOSICIONES DE DICHOS AGENTES, Y MÉTODOS DE USO | |
| BR112015011958A2 (pt) | Utilização de um complexo enzimático, composição alimentícia para animais de criação, e, processo de fabricação do complexo enzimático | |
| CN302458772S (zh) | 门花(六福送宝) |